These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36574312)

  • 41. [Effect of tenofovir disoproxil fumarate antiviral therapy on virus-specific CD8+T Cells function in patients with chronic hepatitis B].
    Duan SP; Zhu LH; Hou LJ; Wang HW; Zhu XW; Hao J
    Zhonghua Gan Zang Bing Za Zhi; 2021 May; 29(5):421-426. PubMed ID: 34107578
    [No Abstract]   [Full Text] [Related]  

  • 42. Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results.
    Liang X; Gao Z; Xie Q; Zhang J; Sheng J; Cheng J; Chen C; Mao Q; Zhao W; Ren H; Tan D; Niu J; Chen S; Pan C; Tang H; Wang H; Mao Y; Jia J; Ning Q; Xu M; Wu S; Li J; Zhang X; Zhang W; Xiong C; Hou J
    Hepatol Int; 2019 May; 13(3):260-269. PubMed ID: 30977033
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
    Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
    Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study.
    Batirel A; Guclu E; Arslan F; Kocak F; Karabay O; Ozer S; Turanli M; Mert A
    Int J Infect Dis; 2014 Nov; 28():153-9. PubMed ID: 25286184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the efficacy and safety of tenofovir and telbivudine in interrupting mother-to-child transmission of hepatitis B virus.
    Zhu B; Lv X; Zhao Z; Chen L; Chen X; Li C; Li S; Dai E
    Medicine (Baltimore); 2021 Nov; 100(44):e27695. PubMed ID: 34871254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?
    Buti M; Casillas R; Riveiro-Barciela M; Homs M; Tabernero D; Salcedo MT; Rodriguez-Frias F; Esteban R
    J Clin Virol; 2015 Jul; 68():61-8. PubMed ID: 26071338
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
    Papatheodoridis GV; Rigopoulou EI; Papatheodoridi M; Zachou K; Xourafas V; Gatselis N; Hadziyannis E; Vlachogiannakos J; Manolakopoulos S; Dalekos GN
    Antivir Ther; 2018; 23(8):677-685. PubMed ID: 30044765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B.
    Seo HY; Lee HA; Ko SY; Wang JH; Kim JH; Choe WH; Kwon SY
    Clin Mol Hepatol; 2017 Jun; 23(2):154-159. PubMed ID: 28479588
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
    Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
    Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
    Heathcote EJ; Marcellin P; Buti M; Gane E; De Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Gurel S; Snow-Lampart A; Borroto-Esoda K; Mondou E; Anderson J; Sorbel J; Rousseau F
    Gastroenterology; 2011 Jan; 140(1):132-43. PubMed ID: 20955704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
    Suzuki F; Suzuki Y; Hosaka T; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2017 May; 52(5):641-651. PubMed ID: 27699721
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
    Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation.
    Kuo YH; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
    Hepatol Int; 2021 Apr; 15(2):301-309. PubMed ID: 33665773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B.
    Liu R; Qiao J; Zhang L; Dou Z
    Medicine (Baltimore); 2024 May; 103(20):e37953. PubMed ID: 38758884
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
    J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience.
    Hu C; Song Y; Tang C; Li M; Liu J; Liu J; Liao M; Zhou F; Zhang YY; Zhou Y
    Clin Ther; 2021 Mar; 43(3):572-581.e3. PubMed ID: 33516527
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection.
    Ahn SH; Kim W; Jung YK; Yang JM; Jang JY; Kweon YO; Cho YK; Kim YJ; Hong GY; Kim DJ; Um SH; Sohn JH; Lee JW; Park SJ; Lee BS; Kim JH; Kim HS; Yoon SK; Kim MY; Yim HJ; Lee KS; Lim YS; Lee WS; Park NH; Jin SY; Kim KH; Choi W; Han KH
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1850-1859.e4. PubMed ID: 30448598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of tenofovir disoproxil fumarate or telbivudine used throughout pregnancy for the prevention of mother-to-child transmission of hepatitis B virus: A cohort study.
    Li Z; Xie B; Yi N; Cai H; Yi W; Gao X
    Eur J Obstet Gynecol Reprod Biol; 2022 Sep; 276():102-106. PubMed ID: 35853269
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
    Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.